Cargando…

Chronic hepatitis C: future treatment

The launch of first-generation protease inhibitors (PIs) is a major step forward in HCV treatment. However, the major advance is up to now restricted to genotype 1 (GT-1) patients. The development of second-wave and second-generation PIs yields higher antiviral potency through plurigenotypic activit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wendt, Astrid, Adhoute, Xavier, Castellani, Paul, Oules, Valerie, Ansaldi, Christelle, Benali, Souad, Bourlière, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891518/ https://www.ncbi.nlm.nih.gov/pubmed/24470777 http://dx.doi.org/10.2147/CPAA.S30338

Ejemplares similares

Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road?
por: Bourlière, Marc, et al.
Publicado: (2018)

Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching
por: Adhoute, Xavier, et al.
Publicado: (2022)

Transarterial chemoembolization (TACE) plus sorafenib: a real winning combination?
por: Adhoute, Xavier, et al.
Publicado: (2020)

Usefulness of the MESH score in a European hepatocellular carcinoma cohort
por: Adhoute, Xavier, et al.
Publicado: (2017)

Detection of IL28B SNP DNA from Buccal Epithelial Cells, Small Amounts of Serum, and Dried Blood Spots
por: Halfon, Philippe, et al.
Publicado: (2012)

“Six-and-twelve” score for outcome prediction of hepatocellular carcinoma following transarterial chemoembolization. In-depth analysis from a multicenter French cohort
por: Adhoute, Xavier, et al.
Publicado: (2020)

Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma: Real-life Data on Liver Disease, Treatment and Prognosis
por: Adhoute, Xavier, et al.
Publicado: (2023)

Expected outcomes and patients’ selection before chemoembolization—“Six-and-Twelve or Pre-TACE-Predict” scores may help clinicians: Real-life French cohorts results
por: Adhoute, Xavier, et al.
Publicado: (2021)

Prospective screening of liver fibrosis in a primary care cohort using systematic calculation of fib-4 in routine results
por: Halfon, Philippe, et al.
Publicado: (2021)

Current and future strategies for the treatment of chronic hepatitis C
por: Alshuwaykh, Omar, et al.
Publicado: (2021)

Longitudinal Liver Stiffness Assessment in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy
por: Martinez, Stella M., et al.
Publicado: (2012)

Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort
por: Adhoute, Xavier, et al.
Publicado: (2017)

Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C
por: Calès, Paul, et al.
Publicado: (2008)

State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization
por: Trucchi, Cecilia, et al.
Publicado: (2016)

Markers of Inflammation and Fibrosis in Alcoholic Hepatitis and Viral Hepatitis C
por: Neuman, Manuela G., et al.
Publicado: (2012)

Response to immunotherapy plus anti‐angiogenic agent combination challenges hepatocellular carcinoma prognostic scores
por: Adhoute, Xavier, et al.
Publicado: (2022)

Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives
por: Degasperi, Elisabetta, et al.
Publicado: (2014)

Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives
por: Chae, Hee Bok, et al.
Publicado: (2013)

Hepatitis C Treatment: current and future perspectives
por: Munir, Saira, et al.
Publicado: (2010)

Treatment of hepatitis C virus infection in the future
por: Kanda, Tatsuo, et al.
Publicado: (2013)

Current status and future directions in the management of chronic hepatitis C
por: Aman, Wosen, et al.
Publicado: (2012)

Treatment of people diagnosed with chronic hepatitis C virus infection
por: Bulterys, Marc, et al.
Publicado: (2018)

HCV cure without interferon
por: Bourlière, Marc
Publicado: (2014)

New anti HCV drugs in the pipeline
por: Bourlière, Marc
Publicado: (2010)

Surgical treatment of tertiary hyperparathyroidism: does one fit for all?
por: Casella, Claudio, et al.
Publicado: (2023)

Interferon-Based Therapy for Chronic Hepatitis C: Current and Future Perspectives
por: Re, Valli De
Publicado: (2010)

New treatments for chronic hepatitis C
por: Jang, Jae Young, et al.
Publicado: (2010)

Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus
por: Halfon, Philippe, et al.
Publicado: (2005)

A Synopsis of Hepatitis C Virus Treatments and Future Perspectives
por: Medina, Christian, et al.
Publicado: (2023)

Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France
por: Marcellin, Patrick, et al.
Publicado: (2016)

How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma
por: Raoul, Jean-Luc, et al.
Publicado: (2016)

Future complications of chronic hepatitis C in a low-risk area: projections from the hepatitis c study in Northern Norway
por: Kileng, H., et al.
Publicado: (2017)

Current treatment of chronic hepatitis B: Clinical aspects and future directions
por: Zhu, Minmin, et al.
Publicado: (2022)

Recent trends in the treatment of chronic hepatitis C
por: Jun, Dae Won, et al.
Publicado: (2012)

158 Hepatitis C Treatment Update: Current Status and Future Direcctions
por: Kottilil, Shyam
Publicado: (2014)

Economic evaluation of treatments for chronic hepatitis B
por: Wiens, Astrid, et al.
Publicado: (2013)

Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US
por: Zhang, Sai, et al.
Publicado: (2015)

Prophages in Salmonella enterica: a driving force in reshaping the genome and physiology of their bacterial host?
por: Wahl, Astrid, et al.
Publicado: (2018)

Remodeling of B-Cell Subsets in Blood during Pegylated IFNα-2a Therapy in Patients with Chronic Hepatitis B Infection
por: Aspord, Caroline, et al.
Publicado: (2016)

On the future of therapeutic vaccination in chronic hepatitis B
por: Aguilar Rubido, Julio Cesar
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ql3tbd9i1gmdk0utii87v2t8vn